Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures

Steve S Chung, Jacqueline A French, Jacek Kowalski, Gregory L Krauss, Sang Kun Lee, Maciej Maciejowski, William E Rosenfeld, Michael R Sperling, Sarah Mizne, Marc Kamin, Steve S Chung, Jacqueline A French, Jacek Kowalski, Gregory L Krauss, Sang Kun Lee, Maciej Maciejowski, William E Rosenfeld, Michael R Sperling, Sarah Mizne, Marc Kamin

Abstract

Objective: To evaluate the efficacy and safety of adjunctive cenobamate 200 mg/d in patients with uncontrolled focal (partial-onset) seizures despite treatment with 1 to 3 antiepileptic drugs.

Methods: In this multicenter, double-blind, placebo-controlled study, adults 18 to 65 years of age with focal seizures were randomized 1:1 (cenobamate:placebo) after an 8-week baseline period. The 12-week double-blind treatment period consisted of a 6-week titration phase and a 6-week maintenance phase. The primary outcome was percent change in seizure frequency (from baseline) per 28 days during double-blind treatment.

Results: Two hundred twenty-two patients were randomized; 113 received cenobamate and 109 received placebo; and 90.3% and 90.8% of patients, respectively, completed double-blind treatment. Median baseline seizure frequency was 6.5 in 28 days (range 0-237). Compared to placebo, cenobamate conferred a greater median percent seizure reduction (55.6% vs 21.5%; p < 0.0001) The responder rate (≥50% reduction in seizure frequency) was 50.4% for cenobamate and 22.2% for placebo (p < 0.0001). Focal seizures with motor component, impaired awareness, and focal to bilateral tonic-clonic seizures were significantly reduced with cenobamate vs placebo. During maintenance, 28.3% of cenobamate-treated and 8.8% of placebo-treated patients were seizure-free. Treatment-emergent adverse events reported in >10% in either group (cenobamate vs placebo) were somnolence (22.1% vs 11.9%), dizziness (22.1% vs 16.5%), headache (12.4% vs 12.8%), nausea (11.5% vs 4.6%), and fatigue (10.6% vs 6.4%).

Conclusion: Adjunctive treatment with cenobamate 200 mg/d significantly improved seizure control in adults with uncontrolled focal seizures and was well tolerated.

Clinicaltrialsgov identifier: NCT01397968.

Classification of evidence: This study provides Class I evidence that, for patients with uncontrolled focal seizures, adjunctive cenobamate reduces seizures.

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Figures

Figure 1. Patient disposition
Figure 1. Patient disposition
ITT = intention-to-treat.
Figure 2. Median percent reduction in seizure…
Figure 2. Median percent reduction in seizure frequency from baseline and ≥50% responder rates (ITT population)
(A) Median percent reduction in seizure frequency normalized to 28-day rate. (B) Responder rates during the double-blind period. Responder defined as ≥50 reduction in seizure frequency. ITT = intention-to-treat.
Figure 3. Median percent reduction for focal…
Figure 3. Median percent reduction for focal seizure types (ITT population)
ITT = intention-to-treat. Seizure frequency normalized to 28-day rate.
Figure 4. Post hoc responder rates during…
Figure 4. Post hoc responder rates during the maintenance phase
(A) Responder rates during the 6-week maintenance phase (intention-to-treat population who took ≥1 dose of study drug during the maintenance phase n = 208). (B) Responder rates during the 6-week maintenance phase (completer population n = 201). Responder defined as ≥75%, 90%, or 100% reduction in seizure frequency during the maintenance phase. CI = confidence interval; OR = odds ratio.
Figure 5. Median percent reduction from baseline…
Figure 5. Median percent reduction from baseline in seizure frequency per 28 days over sequential 4-week intervals (completer population)
*p = 0.001, **p < 0.001 vs placebo.

References

    1. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol 2018;75:279–286.
    1. Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012;78:1548–1554.
    1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314–319.
    1. Tian N, Boring M, Kobau R, Zack MM, Croft JB. Active epilepsy and seizure control in adults—United States, 2013 and 2015. MMWR Morb Mortal Wkly Rep 2018;67:437–442.
    1. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res 2013;103:2–30.
    1. Nakamura M, Cho JH, Shin HS, Jang IS. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol 2019;855:175–182.
    1. Sharma R, Song WS, Nakamura M, et al. . Effects of cenobamate on GABA-A receptor modulation. Presented at American Epilepsy Society Annual Meeting; November 30–December 4, 2018; New Orleans, LA. Abstract 3.306.
    1. Kasteleijn-Nolst Trenité D, DiVentura BD, Pollard JR, Krauss GL, Mizne S, French JA. Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089). Neurology 2019;93:e559–e567.
    1. Scheffer IE, Berkovic S, Capovilla G, et al. . ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58:512–521.
    1. Fisher RS, Cross JH, French JA, et al. . Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58:522–530.
    1. Vernillet L, Kamin M. Drug–drug interactions between cenobamate and other antiepileptic drugs: results from phase I studies with carbamazepine, phenobarbital, phenytoin, and divalproex sodium. Clin Pharmacol Ther 2018;103(suppl S1):S91. Abstract.
    1. Greene S, Kwak C, Kamin M, Vernillet L. The effect of cenobamate on the single dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. Clin Pharmacol Ther 2019;105(suppl 1):S97. Abstract.
    1. Gil-Nagel A, Zaccara G, Baldinetti F, Leon T. Add-on treatment with pregabalin for partial seizures with or without generalisation: pooled data analysis of four randomised placebo-controlled trials. Seizure 2009;18:184–192.
    1. Peeters K, Adriaenssen I, Wapenaar R, Neto W, Pledger G. A pooled analysis of adjunctive topiramate in refractory partial epilepsy. Acta Neurol Scand 2003;108:9–15.
    1. Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. . Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 2013;54:1481–1489.
    1. Ben-Menachem E, Mameniskiene R, Quarato PP, et al. . Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology 2016;87:314–323.
    1. Costa J, Fareleira F, Ascencao R, Borges M, Sampaio C, Vaz-Carneiro A. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia 2011;52:1280–1291.
    1. Krauss GL, Serratosa JM, Villanueva V, et al. . Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78:1408–1415.
    1. French JA, Krauss GL, Biton V, et al. . Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012;79:589–596.
    1. French JA, Krauss GL, Steinhoff BJ, et al. . Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013;54:117–125.
    1. Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia 2014;55:47–56.
    1. Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 2014;55:57–66.
    1. Klein P, Schiemann J, Sperling MR, et al. . A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia 2015;56:1890–1898.
    1. Biton V, Rogin JB, Krauss G, et al. . Adjunctive eslicarbazepine acetate: a pooled analysis of three phase III trials. Epilepsy Behav 2017;72:127–134.
    1. Chung SS, Fakhoury TA, Hogan RE, et al. . Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study. Epilepsia 2014;55:1077–1087.
    1. French JA, Baroldi P, Brittain ST, Johnson JK. Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial. Acta Neurol Scand 2014;129:143–153.
    1. Sperling MR, Abou-Khalil B, Harvey J, et al. . Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia 2015;56:244–253.
    1. Chung S, Ben-Menachem E, Sperling MR, et al. . Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs 2010;24:1041–1054.
    1. Hesdorffer DC, Tomson T, Benn E, et al. . Combined analysis of risk factors for SUDEP. Epilepsia 2011;52:1150–1159.
    1. French JA, Abou-Khalil BW, Leroy RF, et al. . Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011;76:1555–1563.
    1. Chung S, Sperling MR, Biton V, et al. . Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010;51:958–967.
    1. Josephson CB, Patten SB, Bulloch A, et al. . The impact of seizures on epilepsy outcomes: a national, community-based survey. Epilepsia 2017;58:764–771.
    1. Leppik I, De Rue K, Edrich P, Perucca E. Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience. Epileptic Disord 2006;8:118–130.
    1. Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia 2007;48:1303–1307.
    1. Carpay JA, Aldenkamp AP, van Donselaar CA. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure 2005;14:198–206.
    1. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007;48:1223–1244.
    1. Borrelli EP, Lee EY, Descoteaux AM, Kogut SJ, Caffrey AR. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US Food and Drug Administration Adverse Event Reporting System. Epilepsia 2018;59:2318–2324.
    1. Sperling M, Klein P, Kamin M. Safety of cenobamate (YKP3089) as adjunctive treatment for uncontrolled partial seizures in a large, multicenter, open-label study [abstract]. Presented at American Epilepsy Society Annual Meeting; November 30–December 4, 2018; New Orleans, LA. Abstract 1.303.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel